BTX - BTX STOCK NEWS

BROOKLYN, July 26, 2022 – Brooklyn ImmunoTherapeutics (Nasdaq: BTX) announces results from the INSPIRE phase 2 trial of IRX-2, an immunotherapy for stage II, III, or IVA squamous cell carcinoma of the oral cavity. With 150 patients enrolled, the trial reported a median Event-Free Survival (EFS) of 48.3 months in the treatment arm, exceeding the control arm. Safety profiles showed higher adverse events in the treatment group (55.9% vs 40%). The findings indicate a potential benefit for patients not receiving chemotherapy, particularly those with advanced disease. The company plans to present these results at an upcoming conference.

Brooklyn ImmunoTherapeutics (Nasdaq:BTX) announced on June 17, 2022, that it received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share. The company has 180 days until December 14, 2022, to regain compliance by achieving a minimum bid price of $1.00 for 10 consecutive business days. The notice does not immediately affect trading. Brooklyn is actively monitoring its stock price and considering options for compliance.

Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) announced the appointment of four new board members effective June 5, 2022, as part of its strategic growth plan. The new members include Matt Angel, Ph.D., Gregory Fiore, MD, Nicholas Singer, and Bill Wexler, who bring extensive experience in biotechnology and finance. This transition follows the departure of four previous board members. The company aims to advance its initiatives in cytokine, gene editing, and cell therapy for cancer and genetic diseases, positioning itself for future growth.

BROOKLYN, May 31, 2022 - Brooklyn ImmunoTherapeutics has appointed Matt Angel, Ph.D., as Interim Chief Executive Officer, replacing Howard Federoff, who is leaving to pursue new ventures. Andrew Jackson joins as Chief Financial Officer. Angel's experience in cell therapy and mRNA technology is crucial for advancing Brooklyn’s development programs. The company postponed its 2022 Annual Meeting, originally set for June 7, 2022, with new dates to be announced. Brooklyn focuses on cytokine and gene editing therapies for various diseases.

Brooklyn ImmunoTherapeutics (Nasdaq: BTX) announced it received a notice from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the failure to file its Quarterly Report for Q1 2022. The company is working diligently to complete the report and intends to file it promptly. Brooklyn has 60 days to file the report or submit a Compliance Plan, with the possibility of an extension to November 18, 2022, if accepted by Nasdaq. The notice does not have an immediate effect on the listing of Brooklyn’s shares.

Brooklyn ImmunoTherapeutics has expanded its team with new scientific hires and opened a 5,200 square foot R&D facility in San Diego, enhancing its capabilities in cell therapies and genetic medicines. The facility will support translational research and IND-enabling studies, aiming to treat cancer and genetic disorders. The team includes experts with over 12 years in pluripotent stem cell research. Brooklyn's key program, IRX-2, is in Phase 2B trials for head and neck cancer, following promising Phase 2A results.

Brooklyn ImmunoTherapeutics (Nasdaq: BTX) reported its financial results for Q4 and the full year ended December 31, 2021. The company appointed new executives and transitioned to the Nasdaq Global Market while being added to both the Nasdaq and ICE Biotechnology Indexes. In 2021, Brooklyn raised over $52 million and completed the acquisition of Novellus, enhancing its gene therapy platform. For 2021, operating expenses totaled $113.6 million, with a net loss of $122.3 million. Despite increased expenses, cash reserves improved significantly to $17 million by year's end.

Brooklyn ImmunoTherapeutics (Nasdaq: BTX) announced the completion of a private placement, raising approximately $12 million from a leading healthcare investor. The company issued 6,857,142 units at $1.75 per unit, each comprising one share of common stock and a warrant to purchase shares at $1.91 each over five and a half years. Proceeds will support general working capital. The securities sold are subject to resale registration with the SEC.

Brooklyn ImmunoTherapeutics (Nasdaq: BTX) has announced a definitive agreement to sell securities in a private placement, expected to generate approximately $12 million in gross proceeds. The company will issue 6,857,142 units at $1.75 each, each comprising one share of common stock and a warrant at an exercise price of $1.91. The placement is set to close around March 9, 2022. The net proceeds will be used for general working capital. Brooklyn is focused on treatment options for cancer and other diseases through innovative therapies, with ongoing clinical programs.